Vera Therapeutics VERA Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's change in accrued liabilities?
- Vera Therapeutics (VERA) reported change in accrued liabilities of -$437K in Q1 2026.
- How has Vera Therapeutics's change in accrued liabilities changed year-over-year?
- Vera Therapeutics's change in accrued liabilities increased by 90.9% year-over-year, from -$4.78M to -$437K.
- What is the long-term trend for Vera Therapeutics's change in accrued liabilities?
- Over 2 years (2021 to 2025), Vera Therapeutics's change in accrued liabilities has grown at a 63.6% compound annual growth rate (CAGR), from $5.39M to $14.44M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.